NHS Guidance on Using Jardiance with Rybelsus NICE guidance on type 2 diabetes management (NG28, updated regularly) provides the framework for prescribing decisions regarding Jardiance and Rybelsus within the NHS
While both aim to support fat loss, their ingredients, mechanisms, and safety profiles differ significantly
Global NASH Council, American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, European Liver Patients' Association - ELPA, Global Liver Institute, Priti Chawla, Obesity Matters, American Diabetes Association Fatty Liver Alliances Post GLP-1 receptor agonists (GLP-1RAs) show promise in managing metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing hepatic steatosis, resolving MASH, and mitigating fibrosis progression
Patients often report improvements in conditions associated with excess body fat, such as lower cholesterol, blood pressure, and blood sugar levels
Patients can be treated not as passive recipients of a magic shot, but as active participants in their health journey with coaching, tools, and a tailored treatment plan that meets them where they are